Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I posted information on the ARS issue long ago. For the most part my concerns..

See my post quoting the SEC statement

http://agoracom.com/ir/patriot/forums/discussion/topics/346221-deutsche-settlements/messages/1164622#message

  • Each firm will offer to purchase ARS at par from individuals, charities, and small or medium businesses that purchased those ARS from the firm, even if those customers moved their accounts.
  • Each firm will use its best efforts to provide liquidity solutions for institutional and other customers and will not take advantage of liquidity solutions for its own inventory before making those solutions available to these customers.
  • Each firm will pay eligible customers who sold their ARS below par the difference between par and the sale price of the ARS.

The ARS are valued at par.

The question is if RG can negotiate an immediate indemnification or the liquidity solution for an "other" status.

Share
New Message
Please login to post a reply